Trader Asensus Surgical, Inc. - ASXC CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Écart | 0.0450 | ||||||||
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.030779% | ||||||||
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | -0.013666% | ||||||||
Durée des frais en overnight | 22:00 (UTC) | ||||||||
Quantité minimale négociée | 1 | ||||||||
Devise | USD | ||||||||
Marge | 20% | ||||||||
Bourse | United States of America | ||||||||
Commission sur la négociation | 0% |
*Information provided by Capital.com
Fermeture précédente* | 0.7311 |
Ouvert* | 0.6012 |
Variation sur 1 an* | -22.92% |
Fourchette du jour* | 0.6012 - 0.6806 |
Fourchette sur 52 semaines | 0.28-0.92 |
Volume moyen (10 jours) | 1.75M |
Volume moyen (3 mois) | 24.04M |
Capitalisation boursière | 178.58M |
Ratio C/B | -100.00K |
Actions en circulation | 236.84M |
Revenu | 7.10M |
EPS | -0.31 |
Dividende (rendement en %) | N/A |
Bêta | 1.80 |
Prochaine date de publication des résultats | Feb 27, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Clôture | Change | Change (%) | Ouverture | High | Low |
---|---|---|---|---|---|---|
Feb 6, 2023 | 0.6688 | 0.0803 | 13.64% | 0.5885 | 0.6853 | 0.5885 |
Feb 3, 2023 | 0.7311 | 0.0070 | 0.97% | 0.7241 | 0.7748 | 0.7181 |
Feb 2, 2023 | 0.7201 | -0.0244 | -3.28% | 0.7445 | 0.7723 | 0.7167 |
Feb 1, 2023 | 0.7239 | -0.0658 | -8.33% | 0.7897 | 0.7948 | 0.6683 |
Jan 31, 2023 | 0.7715 | -0.0313 | -3.90% | 0.8028 | 0.8268 | 0.7680 |
Jan 30, 2023 | 0.7980 | 0.0200 | 2.57% | 0.7780 | 0.8346 | 0.7780 |
Jan 27, 2023 | 0.7981 | -0.0010 | -0.13% | 0.7991 | 0.8546 | 0.7580 |
Jan 26, 2023 | 0.8093 | 0.1239 | 18.08% | 0.6854 | 0.8294 | 0.6683 |
Jan 25, 2023 | 0.6726 | 0.0043 | 0.64% | 0.6683 | 0.6882 | 0.6583 |
Jan 24, 2023 | 0.6677 | -0.0277 | -3.98% | 0.6954 | 0.6954 | 0.6611 |
Jan 23, 2023 | 0.6597 | 0.0114 | 1.76% | 0.6483 | 0.7028 | 0.6483 |
Jan 20, 2023 | 0.6416 | -0.0167 | -2.54% | 0.6583 | 0.6803 | 0.6284 |
Jan 19, 2023 | 0.6481 | 0.0024 | 0.37% | 0.6457 | 0.6660 | 0.6084 |
Jan 18, 2023 | 0.5981 | -0.0973 | -13.99% | 0.6954 | 0.7099 | 0.5885 |
Jan 17, 2023 | 0.6583 | 0.0424 | 6.88% | 0.6159 | 0.7172 | 0.6084 |
Jan 13, 2023 | 0.5865 | 0.1246 | 26.98% | 0.4619 | 0.5931 | 0.4588 |
Jan 12, 2023 | 0.4682 | 0.0252 | 5.69% | 0.4430 | 0.4740 | 0.4291 |
Jan 11, 2023 | 0.4409 | 0.0039 | 0.89% | 0.4370 | 0.4486 | 0.4370 |
Jan 10, 2023 | 0.4438 | 0.0051 | 1.16% | 0.4387 | 0.4484 | 0.4189 |
Jan 9, 2023 | 0.4418 | -0.0114 | -2.52% | 0.4532 | 0.4577 | 0.4289 |
Asensus Surgical, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Revenu total | 1.519 | 7.111 | 24.102 | 8.531 | 3.175 | 8.232 |
Revenu | 1.519 | 7.111 | 24.102 | 8.531 | 3.175 | 8.232 |
Coût des recettes, total | 1.069 | 6.727 | 16.171 | 20.731 | 5.166 | 11.096 |
Résultat brut | 0.45 | 0.384 | 7.931 | -12.2 | -1.991 | -2.864 |
Total des frais d'exploitation | 125.168 | 69.038 | 73.254 | 163.106 | 63.564 | 70.004 |
Total des frais de vente/Généraux/Admin | 19.964 | 29.811 | 39.59 | 46.772 | 27.201 | 32.718 |
Recherche et développement | 29.273 | 21.989 | 21.823 | 22.468 | 16.621 | 19.348 |
Depreciation / Amortization | 6.967 | 7.858 | 10.868 | 10.301 | 10.801 | 11.254 |
Charges (revenus) inhabituelles | 67.413 | 0 | -14.187 | 72.387 | 0.851 | -2.847 |
Other Operating Expenses, Total | 0.482 | 2.653 | -1.011 | -9.553 | 2.924 | -1.565 |
Produits d'exploitation | -123.649 | -61.927 | -49.152 | -154.575 | -60.389 | -61.772 |
Produits (charges) d'intérêts, nets Hors exploitation | -1.889 | -85.869 | -17.128 | -1.783 | -0.32 | -1.761 |
Autres, nets | 0.035 | -0.3 | 1.126 | -0.967 | -0.119 | 1.296 |
Résultat net avant impôts | -125.503 | -148.096 | -65.154 | -157.325 | -60.828 | -62.237 |
Résultat net après impôts | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Résultat net avant éléments extra | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Résultat net | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Résultat net dilué | -119.98 | -144.796 | -61.777 | -154.201 | -60.023 | -62.462 |
Moyenne pondérée des actions diluées | 8.62962 | 11.4418 | 15.9384 | 17.737 | 70.809 | 226.96 |
BPA dilué hors éléments extraordinaires | -13.9033 | -12.655 | -3.87599 | -8.69375 | -0.84767 | -0.27521 |
BPA dilué normalisé | -8.8256 | -12.655 | -4.45456 | -5.88489 | -0.83986 | -0.28337 |
Total des éléments extraordinaires | 0 | |||||
Total Adjustments to Net Income | -0.711 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Revenu total | 2.083 | 1.102 | 2.571 | 2.476 | 1.066 |
Revenu | 2.083 | 1.102 | 2.571 | 2.476 | 1.066 |
Coût des recettes, total | 3.112 | 2.347 | 3.35 | 2.287 | 1.823 |
Résultat brut | -1.029 | -1.245 | -0.779 | 0.189 | -0.757 |
Total des frais d'exploitation | 17.496 | 14.339 | 20.009 | 18.16 | 20.019 |
Total des frais de vente/Généraux/Admin | 7.045 | 7.41 | 9.108 | 9.155 | 9.252 |
Recherche et développement | 4.215 | 4.089 | 4.469 | 6.575 | 6.428 |
Depreciation / Amortization | 2.867 | 2.862 | 2.804 | 2.721 | 2.67 |
Charges (revenus) inhabituelles | 0 | -2.847 | 0 | 0 | |
Other Operating Expenses, Total | 0.257 | 0.478 | 0.278 | -2.578 | -0.154 |
Produits d'exploitation | -15.413 | -13.237 | -17.438 | -15.684 | -18.953 |
Produits (charges) d'intérêts, nets Hors exploitation | -1.936 | 0.074 | 0.057 | 0.044 | 0.055 |
Autres, nets | -0.029 | -0.007 | 1.344 | -0.012 | -0.146 |
Résultat net avant impôts | -17.378 | -13.17 | -16.037 | -15.652 | -19.044 |
Résultat net après impôts | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Résultat net avant éléments extra | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Résultat net | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Résultat net dilué | -17.34 | -13.172 | -16.069 | -15.881 | -19.128 |
Moyenne pondérée des actions diluées | 204.992 | 233.25 | 234.337 | 234.94 | 235.892 |
BPA dilué hors éléments extraordinaires | -0.08459 | -0.05647 | -0.06857 | -0.0676 | -0.08109 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA dilué normalisé | -0.08459 | -0.06441 | -0.06857 | -0.0676 | -0.08109 |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total de l'actif à court terme | 38.016 | 112.994 | 101.583 | 27.955 | 34.013 | 113.297 |
Espèces et placements à court terme | 24.165 | 91.217 | 72.851 | 9.598 | 16.363 | 98.391 |
Trésorerie et équivalents | 24.165 | 91.217 | 21.061 | 9.598 | 16.363 | 18.129 |
Total des créances, nettes | 1.976 | 3.038 | 8.595 | 3.336 | 3.985 | 2.06 |
Accounts Receivable - Trade, Net | 0.621 | 1.536 | 8.56 | 0.62 | 1.115 | 0.749 |
Total Inventory | 7.883 | 10.817 | 10.941 | 10.653 | 10.034 | 8.634 |
Prepaid Expenses | 3.992 | 7.922 | 9.196 | 4.368 | 3.631 | 3.255 |
Total Assets | 176.249 | 250.251 | 239.307 | 74.779 | 78.258 | 186.473 |
Property/Plant/Equipment, Total - Net | 5.772 | 6.67 | 6.337 | 7.006 | 11.542 | 16.319 |
Property/Plant/Equipment, Total - Gross | 12.345 | 15.888 | 17.499 | 17.974 | 25.802 | 26.008 |
Accumulated Depreciation, Total | -6.573 | -9.218 | -11.162 | -10.968 | -14.26 | -9.689 |
Goodwill, Net | 68.697 | 71.368 | 80.131 | 0 | ||
Intangibles, Net | 53.01 | 52.638 | 50.463 | 31.066 | 22.267 | 9.892 |
Note Receivable - Long Term | 0.266 | 0 | ||||
Other Long Term Assets, Total | 10.488 | 6.581 | 0.793 | 8.752 | 10.436 | 9.53 |
Total Current Liabilities | 30.689 | 28.84 | 21.819 | 13.023 | 10.283 | 9.85 |
Accounts Payable | 3.984 | 3.771 | 4.433 | 3.579 | 1.965 | 3.448 |
Accrued Expenses | 7.883 | 10.379 | 9.228 | 8.553 | 6.301 | 5.859 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 7.997 | 4.788 | 0 | 1.228 | 0 | |
Other Current Liabilities, Total | 10.825 | 9.902 | 8.158 | 0.891 | 0.789 | 0.543 |
Total Liabilities | 58.379 | 71.403 | 70.786 | 19.244 | 16.689 | 17.227 |
Total Long Term Debt | 4.995 | 8.385 | 28.937 | 0 | 1.587 | 0 |
Long Term Debt | 4.995 | 8.385 | 28.937 | 0 | 1.587 | 0 |
Deferred Income Tax | 10.397 | 8.389 | 4.72 | 1.392 | 0 | |
Other Liabilities, Total | 12.298 | 25.789 | 15.31 | 4.829 | 4.819 | 7.377 |
Total Equity | 117.87 | 178.848 | 168.521 | 55.535 | 61.569 | 169.246 |
Common Stock | 0.115 | 0.199 | 0.216 | 0.021 | 0.116 | 0.235 |
Additional Paid-In Capital | 426.609 | 621.261 | 676.373 | 720.484 | 781.397 | 954.649 |
Retained Earnings (Accumulated Deficit) | -302.844 | -447.64 | -509.406 | -663.6 | -722.912 | -785.374 |
Treasury Stock - Common | -0.241 | 0 | ||||
Other Equity, Total | -5.769 | 5.028 | 1.338 | -1.37 | 2.968 | -0.264 |
Total Liabilities & Shareholders’ Equity | 176.249 | 250.251 | 239.307 | 74.779 | 78.258 | 186.473 |
Total Common Shares Outstanding | 8.89867 | 15.3288 | 16.6413 | 20.6913 | 116.231 | 235.219 |
Investissements à court terme | 51.79 | 0 | 80.262 | |||
Redeemable Preferred Stock | 0 | 0 | ||||
Total Preferred Shares Outstanding | 0 | |||||
Other Current Assets, Total | 0.957 | |||||
Long Term Investments | 37.435 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total de l'actif à court terme | 182.325 | 174.007 | 134.807 | 113.297 | 118.684 |
Espèces et placements à court terme | 165.245 | 157.078 | 117.751 | 98.391 | 103.741 |
Trésorerie et équivalents | 165.245 | 157.078 | 59.779 | 18.129 | 24.828 |
Total des créances, nettes | 2.306 | 0.96 | 2.266 | 2.06 | 1.841 |
Accounts Receivable - Trade, Net | 2.306 | 0.96 | 0.955 | 0.749 | 0.53 |
Total Inventory | 11.181 | 12.523 | 11.954 | 8.634 | 9.141 |
Other Current Assets, Total | 3.593 | 3.446 | 0.627 | 0.957 | 0.935 |
Total Assets | 223.615 | 212.004 | 199.759 | 186.473 | 166.56 |
Property/Plant/Equipment, Total - Net | 13.413 | 13.975 | 14.239 | 16.319 | 15.523 |
Intangibles, Net | 18.591 | 15.943 | 12.82 | 9.892 | 7.009 |
Other Long Term Assets, Total | 9.286 | 8.079 | 7.751 | 9.53 | 10.617 |
Total Current Liabilities | 9.508 | 8.307 | 9.421 | 9.85 | 8.653 |
Accounts Payable | 2.327 | 2.653 | 3.231 | 3.448 | 3.521 |
Accrued Expenses | 3.83 | 4.868 | 5.512 | 5.859 | 4.599 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.459 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 0.892 | 0.786 | 0.678 | 0.543 | 0.533 |
Total Liabilities | 17.697 | 16.443 | 18.258 | 17.227 | 15.735 |
Total Long Term Debt | 0.356 | 0 | 0 | 0 | 0 |
Long Term Debt | 0.356 | 0 | 0 | 0 | |
Other Liabilities, Total | 7.833 | 8.136 | 8.837 | 7.377 | 7.082 |
Total Equity | 205.918 | 195.561 | 181.501 | 169.246 | 150.825 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.233 | 0.234 | 0.234 | 0.235 | 0.236 |
Additional Paid-In Capital | 944.907 | 947.249 | 950.242 | 954.649 | 956.557 |
Retained Earnings (Accumulated Deficit) | -740.252 | -753.424 | -769.493 | -785.374 | -804.502 |
Other Equity, Total | 1.03 | 1.502 | 0.518 | -0.264 | -1.466 |
Total Liabilities & Shareholders’ Equity | 223.615 | 212.004 | 199.759 | 186.473 | 166.56 |
Total Common Shares Outstanding | 232.717 | 234.231 | 234.37 | 235.219 | 236.415 |
Total Preferred Shares Outstanding | 0 | 0 | |||
Investissements à court terme | 57.972 | 80.262 | 78.913 | ||
Prepaid Expenses | 2.209 | 3.255 | 3.026 | ||
Long Term Investments | 30.142 | 37.435 | 14.727 |
- Annuel
- Trimestriel
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Revenu net/Ligne de départ | -119.98 | -144.796 | -61.777 | -154.201 | -59.312 | -62.462 |
Liquidités provenant des activités d'exploitation | -52.386 | -47.295 | -48.493 | -73.484 | -46.675 | -40.659 |
Liquidités provenant des activités d'exploitation | 1.942 | 2.486 | 2.42 | 2.166 | 2.898 | 2.857 |
Amortization | 6.967 | 7.858 | 10.868 | 10.301 | 10.801 | 11.254 |
Deferred Taxes | -5.562 | -3.3 | -3.377 | -3.224 | -1.516 | 0.225 |
Éléments non monétaires | 70.148 | 94.494 | 9.288 | 76.825 | 11.171 | 6.24 |
Intérêts payés en espèces | 1.289 | 0.899 | 1.73 | 2.187 | 0 | 0 |
Variation du fonds de roulement | -5.901 | -4.037 | -5.915 | -5.351 | -10.717 | 1.227 |
Flux de trésorerie liés aux activités d'investissement | -1.361 | 5.509 | -53.481 | 67.645 | -0.003 | -119.668 |
Dépenses d'investissement | -1.361 | -1.991 | -0.77 | -0.437 | -0.003 | -1.368 |
Flux de trésorerie provenant des activités de financement | 49.943 | 104.371 | 26.452 | -5.609 | 53.37 | 161.705 |
Éléments de flux de trésorerie de financement | -1.35 | -7.349 | -2.432 | -0.499 | -0.11 | -1.063 |
Émission (remboursement) d'actions, nette | 58.195 | 112.058 | 15.682 | 26.315 | 50.665 | 162.768 |
Émission (remboursement) de la dette, nette | -6.902 | -0.338 | 13.202 | -31.425 | 2.815 | 0 |
Effets de change | -0.055 | 0.431 | -0.433 | 0.364 | 0.27 | 0.376 |
Variation nette de la trésorerie | -3.859 | 63.016 | -75.955 | -11.084 | 6.962 | 1.754 |
Autres éléments de flux de trésorerie d'investissement, total | 7.5 | -52.711 | 68.082 | 0 | -118.3 | |
Cash Taxes Paid | -0.17 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -17.34 | -30.512 | -46.581 | -62.462 | -19.128 |
Cash From Operating Activities | -10.237 | -18.485 | -27.487 | -40.659 | -15.943 |
Cash From Operating Activities | 0.802 | 1.585 | 2.416 | 2.857 | 0.869 |
Amortization | 2.867 | 5.729 | 8.533 | 11.254 | 2.67 |
Deferred Taxes | -0.038 | -0.036 | -0.004 | 0.225 | 0.084 |
Non-Cash Items | 4.146 | 3.785 | 5.867 | 6.24 | 2.303 |
Changes in Working Capital | -0.674 | 0.964 | 2.282 | 1.227 | -2.741 |
Cash From Investing Activities | -0.395 | -0.7 | -89.07 | -119.668 | 23.045 |
Capital Expenditures | -0.395 | -0.7 | -0.838 | -1.368 | -0.246 |
Cash From Financing Activities | 159.605 | 160.108 | 160.141 | 161.705 | -0.336 |
Financing Cash Flow Items | -0.214 | -1.041 | -1.058 | -1.063 | -0.348 |
Issuance (Retirement) of Stock, Net | 159.819 | 161.149 | 161.199 | 162.768 | 0.012 |
Foreign Exchange Effects | -0.108 | -0.329 | -0.181 | 0.376 | -0.045 |
Net Change in Cash | 148.865 | 140.594 | 43.403 | 1.754 | 6.721 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Other Investing Cash Flow Items, Total | -88.232 | -118.3 | 23.291 | ||
Cash Interest Paid | 0 | ||||
Cash Taxes Paid | -0.029 |
Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.8268 | 11431792 | 575904 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5426 | 3653424 | -20584 | 2022-09-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.1492 | 2721843 | -2318995 | 2022-09-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9254 | 2191771 | 4666 | 2022-09-30 | LOW |
GSA Capital Partners LLP | Hedge Fund | 0.4227 | 1001158 | 629411 | 2022-09-30 | HIGH |
Ergoteles Capital | Hedge Fund | 0.4087 | 967987 | -75876 | 2022-09-30 | HIGH |
Fernando (Anthony C J) | Individual Investor | 0.3475 | 823117 | 0 | 2022-04-18 | |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.345 | 817129 | 0 | 2022-12-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.308 | 729462 | -243844 | 2022-09-30 | LOW |
Milne David Bruce | Individual Investor | 0.2617 | 619884 | 0 | 2022-04-18 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.2491 | 590010 | 171230 | 2022-09-30 | LOW |
SV Health Investors, LLC | Venture Capital | 0.2154 | 510142 | 0 | 2022-09-30 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1753 | 415150 | 0 | 2022-09-30 | LOW |
Hsiao (Jane H) | Individual Investor | 0.1422 | 336895 | 0 | 2022-04-18 | |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.125 | 296100 | 296100 | 2022-09-30 | MED |
DWS Investment Management Americas, Inc. | Investment Advisor/Hedge Fund | 0.1219 | 288600 | 0 | 2022-09-30 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1196 | 283376 | -237674 | 2022-09-30 | MED |
Advisor Group, Inc | Investment Advisor | 0.0903 | 213840 | 22666 | 2022-09-30 | LOW |
Caption Management, LLC | Hedge Fund | 0.085 | 201243 | 0 | 2022-09-30 | HIGH |
Biffi (Andrea) | Individual Investor | 0.0843 | 199738 | 0 | 2022-04-18 |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com GroupTradeurs
Clients actifs par mois
Volume d'investissement par mois
Retrait par mois
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Asensus Surgical, Inc. Company profile
À propos de Asensus Surgical Inc
Asensus Surgical, Inc. est une société de dispositifs médicaux qui numérise l'interface entre le chirurgien et le patient grâce à la chirurgie guidée par la performance. La Société se concentre sur le développement du marché et la commercialisation du système chirurgical Senhance, qui numérise la chirurgie mini-invasive laparoscopique (MIS). Le système Senhance est une plate-forme laparoscopique numérique et multiport conçue pour maintenir les normes MIS laparoscopiques tout en offrant des avantages numériques, tels que la rétroaction haptique, la précision robotique, une ergonomie confortable, une instrumentation avancée, y compris des instruments micro laparoscopiques de trois millimètres (mm), cinq mm instruments articulés, commande de caméra à détection oculaire et instruments standard entièrement réutilisables pour les patients du monde entier. Son système Senhance est utilisé en Europe pour la chirurgie laparoscopique abdominale et pelvienne adulte et pédiatrique, ainsi que pour les opérations thoraciques limitées. Il est également disponible aux États-Unis, au Japon, à Taïwan et en Russie.
- IndustrieMedical Equipment / Supplies / Distribution
- Adresse1 TW ALEXANDER DRIVE, SUITE 160, DURHAM, NC, United States (USA)
- Employés153
- CEODavid Milne
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
1 Tw Alexander Drive
Suite 160
DURHAM
NORTH CAROLINA 27703
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 485 000 traders du monde entier qui ont choisi de trader avec Capital.com